PRMT5 and cancer: Indeed, our data showing that treatment of patient-derived BCSCs with the tool PRMT5 inhibitor GSK591 decreases BCSC frequency and proliferation represent, to our knowledge, the first account of a PRMT5 inhibitor influencing cancer stem cells derived from solid cancers.